4F09B010-97EC-4792-BF5A-42E9EF55894D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 88.0749014454665
- age_years
- 38
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.580
- OXIDATIVE_PHOSPHORYLATION+0.542
- E2F_TARGETS+0.492
- DNA_REPAIR+0.479
- ALLOGRAFT_REJECTION+0.443
- MYC_TARGETS_V2+0.434
- IL6_JAK_STAT3_SIGNALING+0.364
- COAGULATION+0.357
- PANCREAS_BETA_CELLS+0.356
- G2M_CHECKPOINT+0.347
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.384
- UV_RESPONSE_DN-0.379
- MITOTIC_SPINDLE-0.360
- ESTROGEN_RESPONSE_EARLY-0.314
- KRAS_SIGNALING_DN-0.261
- MYOGENESIS-0.256
- ANDROGEN_RESPONSE-0.210
- APICAL_JUNCTION-0.209
- APICAL_SURFACE-0.163
- WNT_BETA_CATENIN_SIGNALING-0.146
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.947 |
| 2 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.945 |
| 3 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.935 |
| 4 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.910 |
| 5 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.907 |
| 6 | 060C8F0B-DAB8-43DB-80C9-3404AFCC0B7D | — | — | 0.902 |
| 7 | AE67DBFD-0DD0-4F86-A19F-D4789F585A2E | — | — | 0.894 |
| 8 | 27875588-7C41-49BB-A4C0-A66D72A12499 | — | — | 0.893 |
| 9 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.892 |
| 10 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.542 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.492 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.479 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.443 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.434 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.364 | Inavolisib | — uncovered |
| COAGULATION | 0.357 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.356 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.347 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.345 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.342 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.332 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.293 | Inavolisib | — uncovered |
| APOPTOSIS | 0.283 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.277 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.262 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.243 | Remibrutinib | — uncovered |